Lipa Shah
Director, Novel Delivery Technologies Novartis
Seminars
Wednesday 2nd December 2026
Panel Discussion: The Investment Landscape for CNS Delivery Technologies: Trends, Drivers & Funding Priorities
3:30 pm
- Assess where capital is concentrating across CNS delivery modalities and identify the key scientific and commercial drivers behind investment decisions
- Define the target product profiles and competitive advantages that make CNS delivery platforms attractive for partnerships and acquisition
- Evaluate the timelines, capital requirements, and key inflection points for advancing CNS delivery technologies from preclinical development to clinical validation
- Examine how cost-of-goods, scalability, and risk profiles influence long-term commercial viability and investor confidence
